reports
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care ConferenceFireside Chat: Monday, March 2, 2026, at 3:10 p.m. ET in Boston, MA Leerink Partners Global Healthcare ConferenceFireside Chat: Monday, March 9, 2026, at 4:20 p.m. ET in Miami Beach, FL The C...
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in...
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the CLARITY Phase 3 trial of solriamfetol in the treatment of major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms. CLARITY (Clinical Assessment of Response in the T...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financia...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively,representing 65% and 66% year-over-year growth AUVELITY® 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively,representing 68% and 74% year-over-year growth SUNOSI® 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively,representing 40% and 32% year-over-year growth SYMBRAVO® 4Q and full year 2025 net product sal...
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthca...
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, at 2:00 p.m. ET. A live webcast of the presentation can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at axsom...
Newtek Bank Receives Awards for Lending Capabilities and for Deposit A...
Newtek Bank Receives Awards for Lending Capabilities and for Deposit Accounts BOCA RATON, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) is pleased that its bank subsidiary, Newtek Bank, N.A., (the “Bank”) was recently recognized for its lending capabilities and for its deposit account offering. The Coleman Report named Newtek Bank “.” The Coleman Report is a leading authority on loan programs of the U.S. Small Business Administration (SBA).NerdWallet honored Newtek Bank for having the “.” In determining the top savings account, NerdWallet evaluated more than 100...
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation w...
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome’s product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from...
NewtekOne, Inc. Retires $95 Million of Senior Unsecured Notes
NewtekOne, Inc. Retires $95 Million of Senior Unsecured Notes BOCA RATON, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) retired $95 million of fixed rate senior notes that matured on February 1, 2026. The 5-year notes, which were publicly traded under the ticker symbol “NEWTZ”, were issued in 2021. The Company funded the $95.0 million repayment with $87.1 million of working capital and a recently completed exchange offer pursuant to which the Company exchanged $7.9 million of NEWTZ notes for a like amount of newly issued NEWTO notes. The NEWTZs were the last remn...
NewtekOne, Inc. Reports 4Q25 and Year-to-Date 2025 Basic and Diluted E...
NewtekOne, Inc. Reports 4Q25 and Year-to-Date 2025 Basic and Diluted EPS of $0.65 and $0.65 and $2.21 and $2.18 Midpoint of 2026 Guidance Range is $2.35/Share BOCA RATON, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (the "Company") (Nasdaq: NEWT) reports its financial and operating results for the three and twelve month periods ended December 31, 2025. Financial Highlights for the three and twelve months ended December 31, 2025: For the three months ended December 31, 2025 ("4Q25"), basic and diluted earnings per share ("EPS") were $0.65 and $0.65, respectively, vs. $0.70 a...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financ...
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update...
NewtekOne, Inc. Reminds Investors of the Upcoming Fourth Quarter and F...
NewtekOne, Inc. Reminds Investors of the Upcoming Fourth Quarter and Full Year 2025 Results Conference Call BOCA RATON, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) will report its fourth quarter 2025 financial results after the market closes on Thursday, January 29, 2026. A conference call to discuss these results will be hosted by Barry Sloane, Chief Executive Officer, and Frank M. DeMaria, Chief Financial Officer, at 4:30 pm ET on Thursday, January 29, 2026. Barry Sloane commented, “We are excited to release fourth quarter and full year 2025 earnings and to ...
NewtekOne, Inc. Announces the Expiration Final Results of Exchange Off...
NewtekOne, Inc. Announces the Expiration Final Results of Exchange Offer for its Outstanding 5.50% Notes due 2026 for its 8.50% Fixed Rate Senior Notes due 2031 and Waiver of Minimum Exchange Condition BOCA RATON, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (“NewtekOne”) today announced that its previously announced offer to exchange (the “Exchange Offer”) any and all of its 5.50% Notes due 2026 (the “Old Notes”) for its newly issued 8.50% Fixed Rate Senior Notes due 2031 (the “New Notes”) had expired as of 5:00 p.m., Eastern time on January 23, 2026 (the “Expiration Date”). A...
NewtekOne, Inc. Closes ALP Loan Securitization with Sale of $295 Milli...
NewtekOne, Inc. Closes ALP Loan Securitization with Sale of $295 Million of Rated Notes Transaction Marks NewtekOne’s 17th and Largest Securitization BOCA RATON, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) announced today that it has closed a $295 million securitization backed by $342 million of Alternative Loan Program (“ALP”) loans. This securitization, NALP Business Loan Trust 2026-1 (“2026-1”), represents the Company’s fourth asset-backed securitization secured by ALP loans and is the Company’s 17th and largest rated securitization. All of the Company’s p...
- Jonathan Moreland
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the ...
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14 (esreboxetine) for the management of fibromyalgia. FORWARD (Fibromyalgia Response with Esreboxetine Evaluated Using a Randomized Withdrawal Research Design) is a Phase 3, double-blind, placebo-controlled, multicenter,...
NewtekOne, Inc. to Report Fourth Quarter 2025 Results and Host a Confe...
NewtekOne, Inc. to Report Fourth Quarter 2025 Results and Host a Conference Call on Thursday, January 29, 2026 BOCA RATON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) will report its fourth quarter 2025 financial results after the market closes on Thursday, January 29, 2026. A conference call to discuss these results will be hosted by Barry Sloane, Chief Executive Officer, and Frank DeMaria, Chief Financial Officer, at 4:30 pm ET on Thursday, January 29, 2026. Please note, to receive a dial-in number for the conference call or to listen to the webcast, interes...
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year ...
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively AUVELITY® preliminary 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively SUNOSI® preliminary 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively SYMBRAVO® preliminary 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively...
NewtekOne, Inc. Announces Extension of Exchange Offer for its Notes du...
NewtekOne, Inc. Announces Extension of Exchange Offer for its Notes due 2026 BOCA RATON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (“NewtekOne”) today announced that the expiration date with respect to its previously announced offer to exchange (the “Exchange Offer”) its outstanding 5.50% Notes due 2026 (the “Old Notes”) for an equal principal amount of newly issued 8.50% Fixed Rate Senior Notes due 2031 (the “New Notes”) has been extended to January 23, 2026 in order to provide holders of Old Notes additional time to participate in the Exchange Offer and exchange their Old ...
NewtekOne, Inc. Posts Investor Day Presentation and Provides 2026 EPS ...
NewtekOne, Inc. Posts Investor Day Presentation and Provides 2026 EPS Guidance Range of $2.15-$2.55 BOCA RATON, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- NewtekOne, Inc. (the “Company” or “NewtekOne”) (NASDAQ: NEWT) has posted to the Investor Relations section of its website () an investor presentation for its previously announced “2026 Analyst and Investor Day” event to be held on January 8, 2026 at 12:00 PM. In addition to hosting investors and analysts in person at the Company’s Boca Raton headquarters, the event is being webcasted live. To access the live webcast, participants should re...
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Su...
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (NDA)...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 i...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) supporting an NDA submission for AXS-12 in narcolepsy. AXS-12 (reboxetine) is a highly se...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.